B
ACHN

Bailard’s Achillion Pharmaceuticals ACHN Stock Holding History

Bailard’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-66,100
Closed -$652K – 261
2015
Q1 		$652K Buy
66,100
+25,000
+61% +$312K 0.09% 134
2014
Q4 		$503K Buy
+41,100
New +$502K 0.07% 148

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bailard's ACHN Position: Q2 2015 in Review

Bailard sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 66,100 shares — an estimated $652K sold.

Bailard first reported a position in ACHN in Q4 2014 and held it in 2 quarters. The position peaked at $652K in Q1 2015. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Bailard reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Bailard sold 66,100 Achillion Pharmaceuticals shares in Q2 2015, an estimated $652K.
  • Bailard first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Bailard's Achillion Pharmaceuticals position peaked at $652K in Q1 2015.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Bailard's 13F filing for Q2 2015, filed 6 Aug 2015.